NDAORALTABLETPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRINSUPRI (brensocatib) is an oral tablet approved in August 2025 for non-cystic fibrosis bronchiectasis, a progressive airway disease. The mechanism of action and pharmacologic class are not yet fully detailed in available data. This represents a new treatment option in a rare respiratory indication with limited prior approved therapies.
Launch13.8 years to LOE
Early-stage launch with zero reported competitors creates significant commercial opportunity and expansion potential for field teams and market development roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Started Dec 2024
214 enrolled
Hidradenitis Suppurativa
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Started Apr 2024
24 enrolled
Healthy Participants
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
Started Dec 2023
20 enrolled
Healthy Volunteers
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Started Oct 2023
288 enrolled
Chronic Rhinosinusitis Without Nasal Polyps
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Started Jul 2023
22 enrolled
Healthy Volunteers
Worked on BRINSUPRI at Insmed? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.